Zydus Cadila will soon apply for the Indian drug regulator's approval to conduct trials of ZyCoV-D on children above 2 years, said Dr Sharvil Patel, the managing director of the company. "We have not started studies for the younger age group (2-12 years).
We are working with regulators to work on a program to do a study in the group. We are going to the regulator with the proposed trial in the next five to seven days.
We hope to do trials very soon," Patel was quoted as saying by news agency ANI. Speaking about the trials of ZyCOV-D on adolescents, he said that no severe side effects related to the vaccine were seen in the 12-18 years age group. "Overall the trials on 28,000 volunteers have been conducted at 50 centres.